Trial reportJournal of interventional cardiology2020
Randomized Clinical Trial of Surgical vs. Percutaneous vs. Hybrid Revascularization in Multivessel Coronary Artery Disease: Residual Myocardial Ischemia and Clinical Outcomes at One Year-Hybrid coronary REvascularization Versus Stenting or Surgery (HREVS).
Trial report in Journal of interventional cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01699048 (Prospective, Single-center, Randomized Trial, Intended to Compare Three Revascularization Strategies in Patients With Multi-vessel Coronary Artery Disease), which is not on this map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective, Single-center, Randomized Trial, Intended to Compare Three Revascularization Strategies in Patients With Multi-vessel Coronary Artery Disease
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Comparison of hybrid coronary revascularization versus coronary artery bypass grafting in patients with multivessel coronary artery disease: a meta-analysis.Journal of cardiothoracic surgery · 2022Pooled it
- Perioperative Outcomes of Multivessel Minimally Invasive Coronary Revascularization at a Specialized Center: A Retrospective Cohort of Complete Surgical and Planned Hybrid Strategies.Journal of clinical medicine · 2026Article
- Robotic Coronary Artery Bypass Grafting: A Narrative Review of Techniques, Evidence, and Future Directions.Journal of clinical medicine · 2026Review
- Long-term safety and effectiveness of hybrid coronary revascularization compared to conventional revascularization strategies: a systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2026Article
- Review
- Current trends in hybrid coronary revascularization.Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery · 2025Review
- Generalized hybrid coronary revascularization vs. conventional off-pump coronary artery bypass grafting for multivessel coronary artery disease.Frontiers in cardiovascular medicine · 2025Article
- Hybrid coronary revascularization vs. PCI in high-risk multivessel coronary artery disease: a two-center, two-year utcome comparison.Frontiers in cardiovascular medicine · 2025Article
- Percutaneous Coronary Intervention Versus Robotic Coronary Bypass for Left Anterior Descending Artery Chronic Total Occlusion.Journal of the Society for Cardiovascular Angiography & Interventions · 2024Article
- Need for repeat revascularisation in hybrid coronary revascularisation vs. percutaneous coronary intervention.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2024Review
- Comparative Efficacy of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in the Treatment of Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Recent Randomized Controlled Trials.Cardiology research · 2024Article
- Minimally Invasive Isolated and Hybrid Surgical Revascularization for Multivessel Coronary Disease: A Single-Center Long-Term Follow-Up.Journal of personalized medicine · 2024Article
- Four case reports of left anterior descending restenosis treated via the internal mammary artery: A literature review.Heliyon · 2024Article
- Minimal-Access Coronary Revascularization: Past, Present, and Future.Journal of cardiovascular development and disease · 2023Review
- Staged Hybrid Coronary Revascularization in Acute Coronary Syndrome.Annals of thoracic surgery short reports · 2023Article
- Assessment of the Graft Quality and Patency during and after Coronary Artery Bypass Grafting.Diagnostics (Basel, Switzerland) · 2023Review
- Robotic advanced hybrid coronary revascularization: Outcomes with two internal thoracic artery grafts and stents.JTCVS techniques · 2022Article
- Hybrid techniques for myocardial regeneration: state of the art and future perspectives.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2022Review
- Objective, observer-independent evaluation of myocardial perfusion and function: role of SPECT.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2022Review
- Revascularization strategies in patients with multivessel coronary artery disease: a Bayesian network meta-analysis.Interactive cardiovascular and thoracic surgery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimOptimal revascularization strategy in multivessel (MV) coronary artery disease (CAD) eligible for percutaneous management (PCI) and surgery remains unresolved. We evaluated, in a randomized clinical trial, residual myocardial ischemia (RI) and clinical outcomes of MV-CAD revascularization using coronary artery bypass grafting (CABG), hybrid coronary revascularization (HCR), or MV-PCI.
methodsConsecutive MV-CAD patients (
resultsData are given, respectively, for the CABG, HCR, and MV-PCI arms. Incomplete revascularization rate was 8.0% vs. 7.7% vs. 5.7% (
conclusionIn this first randomized controlled study comparing CABG, HCR, and MV-PCI, residual myocardial ischemia and MACCE were similar at 12 months. There was no midterm indication of any added value of HCR. Hospital stay and sick-leave duration were shortest with MV-PCI. While longer-term follow-up is warranted, these findings may impact patient and physician choices and healthcare resources utilization. This trial is registered with NCT01699048.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.